dc.contributor.author
Rosada, Adrian
dc.contributor.author
Kassner, Ursula
dc.contributor.author
Weidemann, Felix
dc.contributor.author
König, Maximilian
dc.contributor.author
Buchmann, Nikolaus
dc.contributor.author
Steinhagen-Thiessen, Elisabeth
dc.contributor.author
Spira, Dominik
dc.date.accessioned
2020-08-24T09:00:23Z
dc.date.available
2020-08-24T09:00:23Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/28065
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-27815
dc.description.abstract
Background: Hyperlipidemias are common and the last decades have seen substantially growing evidence of their causative role in the development of atherosclerosis and subsequent cardiovascular diseases. Since hyperlipidemias usually do not cause direct clinical symptoms, they often remain undiagnosed until a serious cardiovascular event occurs. Especially for LDL-hypercholesteremia, there are well-established treatment options available to prevent the occurrence of atherosclerosis. However, there is a lack of knowledge regarding the proper treatment of elderly patients. The goal of this study was to assess the prevalence of hyperlipidemia in a group of young and a group of elderly community-dwelling participants and to determine to what extent treatment of hyperlipidemia should be initiated or required.
Methods: Crossectional data from a total of 2151 subjects (1657 in the elderly group, mean age 69, and 494 in the young group (control group), mean age 29) of the Berlin Aging Study II (BASE-II) were available. Medical history was assessed and recorded by trained physicians and prevalence of lipid disorders was determined with laboratory tests, including a lipid-profile.
Results: A large proportion of subjects (39%) were unaware of an existing lipid disorder. The prevalence of hyperlipidemia was more frequent in the elderly group (76%) compared to the young group (41%). Hypercholesterolemia was the most common diagnosed disorder (64%), followed by hyperlipoproteinemia(a) (18%), hypertriglyceridemia (7%) and combined hyperlipoproteinaemia (5%). Only a minority of this cohort was treated with lipid-lowering medication (17%) and of those treatment targets according to ESC guidelines were reached only in 16.5 %.
Conclusions: Hyperlipidemias appear underdiagnosed and undertreated. As the prevalence of these disorders increases with age and with regard to their role as a major modifiable risk factor for cardiovascular disease it seems to be advisable to aim for more consistent and sustainable screening and treatment of these common disorders.
Trial registration: BASE-II registered with the clinical trial registry Deutsches Register Klinischer Studien (DRKS00009277).
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Hyperlipidemia
en
dc.subject
treatment targets
en
dc.subject
elderly patients
en
dc.subject
cardiovascular disease
en
dc.subject
Lipoprotein(a)
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
92
dcterms.bibliographicCitation.doi
10.1186/s12944-020-01277-9
dcterms.bibliographicCitation.journaltitle
Lipids in Health and Disease
dcterms.bibliographicCitation.originalpublishername
BMC
dcterms.bibliographicCitation.volume
19
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
32410691
dcterms.isPartOf.eissn
1476-511X